Human papillomavirus infection requires the TSG101 component of the ESCRT machinery  by Broniarczyk, Justyna et al.
Human papillomavirus infection requires the TSG101 component
of the ESCRT machinery
Justyna Broniarczyk b, Martina Bergant c, Anna Goździcka-Józeﬁak b,n, Lawrence Banks a,n
a International Centre for Genetic Engineering and Biotechnology, Padriciano 99, I-34149 Trieste, Italy
b Department of Molecular Virology, Adam Mickiewicz University, Umultowska 89, 61-614 Poznan, Poland
c Laboratory for Environmental Research, University of Nova Gorica, Nova Gorica, Slovenia
a r t i c l e i n f o
Article history:
Received 14 February 2014
Returned to author for revisions
10 March 2014
Accepted 6 May 2014
Available online 29 May 2014
Keywords:
HPV
Infection
L2
TSG101
a b s t r a c t
Infection with human papillomaviruses (HPV) requires the minor capsid component L2, which plays an
essential role in directing appropriate endosomal trafﬁcking. Previous studies have indicated an infection
route involving multi-vesicular bodies (MVBs), and an essential element in their biogenesis is the ESCRT
machinery. Here we show that the ESCRT component TSG101 is required for optimal infection with both
HPV-16 and BPV-1, with loss of TSG101 resulting in a decrease in viral infection, whereas overexpressed
TSG101 increases rates of infection. We ﬁnd that L2 proteins from multiple PV types interact with
TSG101 and show that this interaction contributes to an alteration in the subcellular distribution of L2.
In addition, TSG101 can modulate the levels of L2 polyubiquitination. These results demonstrate that
TSG101 plays an important part in infection with diverse PVs, and suggests that trafﬁcking of HPV
through the ESCRT machinery and MVBs is part of infectious virus entry.
& 2014 Elsevier Inc. All rights reserved.
Introduction
Human Papillomaviruses (HPVs) are small non-enveloped viruses
that contain an 8 kb DNA genome encased within an icosahedral
capsid. They infect epithelial cells and their life cycle is intimately
linked to the differentiation of the infected epithelium (Doorbar,
2007). Whilst HPVs predominantly only cause benign epithelial
lesions, a subset of 12 types are deﬁned as cancer-causing, with
tumours arising in the cervix, other anogenital regions, and in the
head and neck. Of these types, HPV-16 is probably the most
important, and is responsible for over 60% of all cervical cancers
world wide (zur Hausen, 1996; Bouvard et al., 2009).
Papillomaviruses (PVs) encode two structural proteins: the
major capsid protein L1, and the minor capsid protein L2. It is
well established that the L1 protein alone can self assemble into
virus-like particles (VLPs); however, such particles are non-
infectious and L2 is required for the correct encapsidation of the
viral genome and for infectious viral entry into the host cell
(Pereira et al., 2009). The PV viral life cycle is tightly connected
to the differentiation program of the infected stratiﬁed epithelium.
PV infection requires the presence of receptors such as heparin
sulphate, proteoglycans and α integrin (Joyce et al., 1999; Giroglou
et al., 2001; Shafti-Keramat et al., 2003; Dasgupta et al., 2011). The
route by which PVs enter basal cells is diverse and appears to
depend upon the virus type: for example, BPV is reported to use
clathrin-mediated endocytosis (Laniosz et al., 2008), HPV-31 a
caveolin-dependent mechanism (Smith et al., 2007), and HPV-16 a
novel clathrin- and caveolin-independent pathway (Spoden
et al., 2008; Schelhaas et al., 2012; Scheffer et al., 2013; Spoden
et al., 2013). Virus capsids disassemble in the late endosomes and/
or lysosomes in a pH-dependent manner, and the subsequent
transport of the viral DNA to the nucleus is facilitated by the minor
capsid protein L2 (Day et al., 1998; Florin et al., 2002). This occurs
through a pathway that involves lysozomal escape of the L2-DNA
complex, in part due to the ability of L2 to interact with
components of the cellular sorting machinery, such as sorting
nexin 17 (Bergant-Marušič et al., 2012). The L2-DNA complex then
trafﬁcs toward the nucleus through a pathway that requires
Dynein-mediated transport (Florin et al., 2006; Schneider et al.,
2011) and accumulates in the trans-Golgi network (Day et al.,
2013). Following nuclear envelope breakdown in mitosis the
L2-DNA complex can then enter the nucleus (Pyeon et al., 2009),
where it is found in close proximity with PML bodies, and where
viral gene expression is believed to initiate (Day et al., 2004). The
viral genome replicates at a low level in the basal layers
of the epithelium, where expression of the non-structural
proteins begins, while high copy-number productive replication
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and expression of the structural proteins take place in the differ-
entiating cells of the more superﬁcial layers, ultimately leading to
the assembly of new infectious virus particles (Doorbar et al., 2012).
Mature viron particles are then produced and released from the
terminally differentiated suprabasal cells (Doorbar, 2007).
During PV infection, endosome acidiﬁcation is an important
element for successful viral infection (Kamper et al., 2006; Smith
et al., 2008; Dabydeen and Meneses, 2009). Recent studies have also
shown that HPV-16 pseudovirions (PsVs) are found within the multi-
vesicular bodies (MVBs) of late endosomes (Schelhaas et al., 2012).
MVBs play an essential role in endosomal/lysozomal cargo sorting and
are major determinants in deciding whether cargoes go for recycling
or lysozomal degradation (Huotari and Helenius, 2011; Katzman et al.,
2002). A critical element in this process is the endosomal sorting
complex required for transport (ESCRT) machinery (Saksena, et al.,
2007). Since HPV was shown to be present within MVBs during
infection, we were interested in determining whether an essential
component of the ESCRT machinery, TSG101, is involved in the PV
infectious entry pathway.
Results
TSG101 is required for efﬁcient HPV-16 infection
Previous studies have shown the potential involvement of MVBs
during the HPV infection process, with accumulation of HPV particles
within MVBs being observed in the later stages of infection (Schelhaas
et al., 2012). Since a critical element in the biogenesis of these bodies
are the ESCRT complexes, especially the TSG101 protein, we were
interested in determining whether TSG101might have any role to play
during HPV infection. To investigate this we performed a series of
infection assays in HaCaT cells using HPV-16 pseudovirions (PsVs)
carrying a luciferase reporter gene. Prior to infection the cells were
transfected either with an siRNA against TSG101, which forms a major
component of the ESCRT-1 complex, or with siRNA against HPV-18 E6/
E7 as a control. The results obtained are shown in Fig. 1 and
demonstrate that loss of TSG101 expression signiﬁcantly reduces the
infection efﬁciency of HPV-16 PsVs. Statistically signiﬁcant reductions
of around 40% were consistently observed. This can be compared with
the reduction of around 70% seen upon ablation of SNX17 (data not
shown), which is also known to be required for efﬁcient HPV infection
(Bergant-Marušič et al., 2012).
To determine whether TSG101 was also required for infection with
other Papillomaviruses, we repeated the assays using BPV-1 PsVs and,
for comparison, the unrelated Merkel Cell Polyoma Virus (MCV) PsVs.
The results in Fig. 1 show that efﬁcient BPV-1 infection also requires
TSG101. Interestingly, loss of TSG101 appears to have no major effect
upon the infection efﬁciency of MCV PsVs, demonstrating that the loss
of TSG101 does not perturb endosomal–lysozomal transport processes
in general and indicating that the TSG101 requirement is speciﬁc for
PV infection.
Having shown that loss of TSG101 could reduce infectionwith HPV,
we then performed a series of studies to determine whether TSG101
overexpression could likewise increase rates of infection with HPV-16
PsVs. HaCaT cells were transfected with TSG101 expression plasmids
and then infected with HPV-16 PsVs. After 24 h, infection was
monitored by measuring luciferase activity and the results obtained
are shown in Fig. 1C. As can be seen, increasing amounts of TSG101
(shown in Fig. 1D) resulted in a statistically signiﬁcant increase in the
α-actinin
TSG101
α-actinin
TSG101
GFP
Fig. 1. Loss of TSG101 reduces HPV-16 and BPV-1 infection. Panel A. HaCaT cells were transfected with siCTRL and siTSG101. After 48 h, cells were exposed to HPV-16, BPV-1
and MCV PsVs carrying a luciferase reporter plasmid. After 24 h the cells were harvested and the luciferase activity measured. The results are expressed as means and error
bars show the standard deviations from at least three independent experiments, where npo0.05. Panel B. Western blot showing the levels of TSG101 in HaCaT cells following
transfection with siCTRL and siTSG101. Alpha-actinin was used as the loading control. Panel C. HaCaT cells were transfected with GFP control expressing plasmid or
increasing amounts of TSG101 GFP plasmid (0.2 μg, 0.3 μg and 0.5 μg as indicated) and infected with HPV-16 PsVs carrying a luciferase reporter plasmid. After 24 h the cells
were harvested and luciferase activity measured. The results are expressed as the means and error bars show the standard deviations from at least three independent
experiments, where nnpo0.01 Panel D. Western blot showing the levels of TSG101 expression following transfection of the HaCaT cells detected using anti-TSG101 antibody
or anti-GFP for the control transfection. Also shown is the Western blot for α-actinin as the loading control.
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efﬁciency of infection with HPV-16 PsVs. Taken together, these results
suggest that the ESCRT-1 component TSG101 is involved in the HPV
infection process.
L2 interaction with TSG101 is conserved across multiple
papillomavirus types
We were next interested in determining how TSG101 might be
involved in HPV infection. To do this we ﬁrst analyzed whether
HPV-16 virion components L1 and L2 could interact with TSG101.
These were expressed as GST fusion proteins and used in pull-
down assays using in vitro translated radiolabelled TSG101. The
results in Fig. 2A demonstrate strong interaction between GST-
16L2 and TSG101, but little or no interaction between GST-16L1
and TSG101. The assay was also performed using TSG101 derived
from HEK293 cells transfected with a TSG101 GFP expression
plasmid. As can be seen from Fig. 2B, HPV-16 L2 also interacts
with cell-derived TSG101. Furthermore the interaction also
appears to be somewhat cold-sensitive, with signiﬁcantly stronger
interaction at room temperature than at 4 1C.
The above infection studies indicate a role for TSG101 in infection
with HPV-16 and with BPV-1. We next investigated whether the L2
proteins from diverse PVs could likewise interact with TSG101. GST-L2
fusion proteins derived from BPV-1, SfPV-1, HPV-11 and, for compar-
ison, HPV-16, were puriﬁed and used in pull-down assays with in vitro
translated, radiolabelled TSG101. The results in Fig. 2C demonstrate
very similar levels of association between TSG101 and the L2 proteins
from diverse PV types, suggesting that L2–TSG101 interactions are
highly conserved across multiple PV types.
Finally we wanted to determine whether HPV-16 L2 could also
associate with endogenous TSG101 in vivo. To do this HEK293 cells
were transfected with GFP-tagged HPV-16 L2 alone, or in combination
with GFP-tagged TSG101. After 24 h the cells were harvested and cell
extracts immunoprecipitated with anti-TSG101 antibody, or as a
control, with anti-HA antibody. Co-immunoprecipitating HPV-16 L2
was then detected by Western blotting using polyclonal rabbit anti-
HPV-16 L2 antibody. The results in Fig. 3 demonstrate a strong
interaction between over-expressed HPV-16 L2 and TSG101, as would
be expected. However, a clear association can also be seen between
endogenous TSG101 and the ectopically expressed HPV-16 L2,
whereas no L2 was detected following immunoprecipitation with
the anti-HA control antibody. These results demonstrate that HPV-16
L2 can also associate with endogenously expressed TSG101 in vivo.
Identiﬁcation of the HPV-16 L2 region required for interaction
with TSG101
To identify the region of L2 that is responsible for binding TSG101,
we generated a series of deletion constructs of HPV-16 L2 which are
shown schematically in Fig. 4A. These were HA/Flag tagged and
transfected into HEK293 cells, together with GFP-tagged TSG101. After
24 h the cells were harvested and immunoprecipitated using anti-HA-
conjugated agarose beads. Co-immunoprecipitating TSG101 was then
detected by Western blotting with anti-TSG101 antibody. The results
shown in Fig. 4B deﬁne a region of the L2 protein spanning residues
319–348 as important for association with TSG101, since the construct
containing only residues 1–319 is impaired in TSG101 interaction,
whereas the 1–348 construct has wild type levels of association.
However, residues between 192 and 319 also seem to be involved,
since only the HPV-16 L2 1–192 mutant has lost all ability to associate
with TSG101.
HPV-16 L2 colocalizes with TSG101
Having shown that TSG101 interacts strongly with HPV-16 L2
we were next interested in determining where the interaction
occurs within the cell. To do this, HaCaT keratinocytes were
transfected with FLAG-HA-tagged HPV-16 L2 expression plasmid
and a GFP-tagged TSG101 expression plasmid. For comparison we
also included the HPV-16 L2 deletion mutant spanning residues
1–192, which was shown above to be defective in TSG101
recognition. After 24 h the cells were ﬁxed and stained and the
patterns of L2 and TSG101 expression ascertained by immuno-
ﬂuorescent staining and confocal microscopy. The results obtained
with wild type HPV-16 L2 and TSG101 are shown in Fig. 5A and
demonstrate that L2 normally has a predominantly nuclear
pattern of expression, consistent with previous studies, whilst
TSG101 displays a largely cytoplasmic pattern of expression, with
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Fig. 2. TSG101 interacts with L2 proteins from different papillomavirus types. Panel A. Puriﬁed HPV-16 L1 and HPV-16 L2 GST fusion proteins were incubated with in vitro
translated and radiolabelled TSG101. After extensive washing the bound proteins were analyzed by SDS PAGE and autoradiography (upper panel). The lower panel shows the
Coomassie-stained gel. Panel B. HEK293 cells were transfected with TSG101 GFP expressing plasmid, and after 24 h the cells were lysed and extracts incubated (at 4 1C and
room temperature) with puriﬁed GST HPV-16 L2 fusion protein and empty GST as a control. Bound proteins were analyzed by Western blotting using anti-TSG101 antibody
(upper panel). The lower panel shows the Ponceau stain of the nitrocellulose membrane. Panel C. The puriﬁed GST L2 fusion proteins were incubated with in vitro translated
and radiolabelled TSG101. After extensive washing the bound proteins were eluted and analyzed by SDS PAGE and autoradiography (upper panel). The lower panel shows the
Coomassie-stained gel.
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evidence of clearly deﬁned dot-like structures, consistent with it
being localized to late endosomal/lysozomal compartments. When
L2 and TSG101 are co-expressed, TSG101 remains predominantly
cytoplasmic, and likewise the bulk of L2 remains within the nucleus.
However, there is also a signiﬁcant accumulation of L2 with TSG101
in the dot-like structures found within the cytoplasm. In contrast, the
HPV-16 L2 mutant (Fig. 5B), that has also lost the carboxy terminal
nuclear localization signal (NLS) (Darshan et al., 2004; Mamoor et al.,
2012), shows a diffuse pattern of expression throughout the cell.
Most importantly, this pattern remains unchanged in the presence of
ectopically expressed TSG101, and no apparent co-localisation is
seen, which correlates with the inability of this mutant to interact
with TSG101. Similar results were also seen in U2OS cells (data not
shown). These results demonstrate that L2 can co-localize with
TSG101 in late endosomal/lysozomal compartments.
TSG101 modulates L2 ubiquitination
One of the major functions of TSG101 is to interact with mono-
ubiquitinated proteins and to protect them from further polyubiqui-
tination (Burgdorf et al., 2004). We were therefore interested in
investigating whether TSG101 might be able to modulate the ubiqui-
tination of HPV-16 L2. To do this HEK293 cells were transfected GFP-
tagged HPV-16 L2, GFP-tagged TSG101 and HA-tagged ubiquitin. After
24 h cells were either treated or not with MG132 to rescue any
proteins from proteasome-mediated degradation, and ubiquitin-
bound proteins were immunoprecipitated using anti-HA conjugated
agarose beads. Ubiquitinated L2 was then detected by Western
blotting using anti-L2 antibody. The results obtained are shown in
Fig. 6 and demonstrate that L2 is subject to a signiﬁcant level of
poly-ubiquitination. Interestingly, this does not change signiﬁcantly in
the presence of MG132, suggesting that ubiquitinated L2 is not
a signiﬁcant substrate for the proteasome. Most importantly, in the
presence of TSG101 there is a dramatic decrease in the levels
of polyubiquitinated L2, however with no major change in total L2
levels. These results indicate that one consequence of the interaction
between TSG101 and L2 is a reduction in the level of poly-
ubiquitinated L2.
Discussion
Infection with HPV requires endocytic uptake and subsequent
acidiﬁcation of the endosome, accompanied by viral uncoating.
During this process, virus particles can be seen in MVBs (Schelhaas
et al., 2012), which play a role during late endosome maturation
(Huotari and Helenius, 2011; Katzmann et al., 2002), suggesting that
steps involved in MVB formation might play a part in the HPV
infection process. An important element in the maturation of MVBs
is the ESCRT complex, which recognizes and sorts ubiquitin-
modiﬁed cargoes into the MVBs. We therefore reasoned that this
complex might be involved in HPV infection and to assess this we
analyzed the role of the major ESCRT component TSG101. We ﬁnd
that, upon loss of TSG101 expression, there is a signiﬁcant decrease
in the levels of infection with HPV-16 PsVs. Likewise, overexpression
of TSG101 increases the levels of infection with HPV-16 PsVs.
Interestingly, this appears to be important also for BPV, suggesting
that the role of TSG101 in PV infection is conserved across diverse PV
Fig. 3. HPV-16 L2 can associate with endogenous TSG101 in vivo. HEK293 cells
were transfected with HPV-16L2 GFP and TSG101 GFP together, or HPV-16L2 GFP
and pCDNA alone. After 24 h the cells were harvested and cell extracts immuno-
precipitated using anti-TSG101 antibody and protein A-conjugated sepharose
beads. As a control, lysates from cells transfected with HPV-16L2 GFP alone were
divided and immunoprecipitated using anti-TSG101 or anti-HA antibody as a
control. Co-immunoprecipitating L2 was then detected by Western blotting using
rabbit anti-HPV-16 L2 antibody (top panel). The two lower panels show the inputs
for L2 and TSG101. Note very strong co-immunoprecipitation when L2 and TSG101
are overexpressed, but still readily detectable co-immunoprecipitating L2 when in
the presence of endogenous TSG101.
Fig. 4. Mapping the region of HPV-16 L2 interacting with TSG101. Panel A. Schematic
showing the different L2 deletion constructs used in the analysis. Panel B. HEK293
cells were co-transfected with the different L2 expression plasmids and TSG101 GFP
and as controls, with TSG101 GFP and pCDNA. After 24 h the cells were harvested
and immunoprecipitations done using anti-HA antibody conjugated agarose beads.
Co-immunoprecipitating TSG101 was then detected by Western blotting using
anti-TSG101 antibody (top panel). The two lower panels show the inputs for
TSG101 and L2.
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types. Based on these results it is tempting to suggest that the ESCRT
machinery is involved in the HPV infection process, although TSG101
has other activities unrelated to this. However preliminary experi-
ments in which the ESCRT component Vps4 is ablated, also results in
a reduction in HPV-16 PsV infection (data not shown), indicating
that the ESCRT machinery is indeed required. Obviously further
studies are required to investigate this further.
In order to investigate how TSG101 might impact on PV
infection, we ﬁrst investigated the ability of TSG101 to recognize
components of the HPV capsid. We found that HPV-16 L2 could
interact strongly with TSG101, whereas HPV-16 L1 did not.
Extending these studies to L2 proteins derived from different
PVs, we could show that the ability to interact with TSG101 is
conserved across a wide evolutionary spectrum of PV types,
ranging from SfPV and BPV to HPV-16 and HPV-11. This is
consistent with the observed effects on infection processes, where
BPV also required TSG101 for optimal levels of infection. We also
mapped the site of TSG101 interaction on HPV-16 L2, and deﬁned
a short stretch of amino acids spanning residues 319–375 as being
important for the interaction. Interestingly, this region of L2 is
highly conserved through evolution, conﬁrming the highly con-
served nature of this interaction.
Previous studies have shown that TSG101 is expressed pri-
marily within endosomal/lysozomal compartments, whilst L2 is
predominantly nuclear. Therefore to investigate how L2 and
TSG101 might interact in vivo, we performed a series of immu-
noﬂuorescence analyses on cells co-expressing HPV-16 L2 and
TSG101. Whilst neither protein induced a dramatic alteration in
the other's pattern of expression, it was quite striking that a
signiﬁcant proportion of L2 became relocalized and was found in
close proximity with TSG101 in the endosomal/lysozomal
structures within the cytoplasm. The speciﬁcity of these effects
was further conﬁrmed using a mutant of L2 that could not
interact with TSG101. The expression pattern of this mutant,
although much more diffuse and cytoplasmic than that of the
wild type L2, which is consistent with a loss of the carboxy
terminal NLS (Darshan et al., 2004; Mamoor et al., 2012),
was completely unaffected by co-expression of TSG101. These
results suggest that a proportion of L2 can co-localize with
vesicular-bound TSG101 even when L2 is not part of the viral
capsid. Whether this might have any relevance for the normal
function of TSG101 and, likewise, whether this might have a role
during other phases of the viral life cycle, remains to be
determined.
Fig. 5. HPV-16 L2 colocalizes with TSG101. Panel A HaCaT cells were cotransfected with FLAG-HA-tagged HPV-16 L2 (full length) and TSG101 GFP expression plasmids. After
24 h the cells were ﬁxed and stained for HPV-16 L2 using anti-HA antibody (red) and TSG101 GFP can be seen in green. Panel B. HaCaT cells were cotransfected with FLAG-
HA-tagged HPV-16 L2 (1-192) and TSG101 GFP expression plasmids and processed as in Panel A.
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One of the major functions of TSG101 is to bind mono-
ubiquitinated proteins and thereby prevent further ubiquitination
from taking place (Burgdorf et al., 2004). In HEK293 cells, poly-
ubiquitination of HPV-16 L2 is easily detectable, although there
does not seem to be any signiﬁcant degree of proteasomal
degradation. In the presence of TSG101, however, there is a
dramatic reduction in the levels of L2 polyubiquitination, with
only one species of L2 being co-immunoprecipitated with ubiqui-
tin in the presence of TSG101, suggesting that this is a mono-
ubiquitinated form of L2. Whether this activity of TSG101 is
relevant for viral infection or, alternatively, is related to the later
stages of viral infection, before L2 is complexed with L1 in the
assembly of new virions, remains to be determined.
Taken together these studies provide compelling evidence of a
functionally signiﬁcant interaction between HPV-16 L2 and the
ESCRT-1 component, TSG101. This interaction can modulate the
localisation of L2 within the cell, and furthermore can reduce the
levels of L2 polyubiquitination. Most importantly, TSG101 plays an
important role in the PV infection process. Whether this reﬂects a
general perturbation of late endosome maturation and MVB
formation upon the loss of TSG101 expression, and subsequent
alteration in the fate of the infecting virions (Doyotte et al., 2005;
Razi and Futter, 2006; Bache et al., 2006), or is a direct conse-
quence of TSG101 affecting the sorting of L2-DNA complexes
remains to be determined.
Materials and methods
Plasmids
The pCA plasmid expressing HPV-16 L2 protein has been
described previously (Bergant-Marušič et al., 2012). Deletion mutants
of HPV-16 L2 protein were generated using the Invitrogen GeneTailor
system and veriﬁed by sequencing. Oligonucleotides were designed
in-house and were synthesized by MWG Biotech AG.
GST HPV-16 L1, GST HPV-16 L2, GST BPV-1 L2, GST SfPV-1 L2
and GST HPV-11 L2 as well as BPV-1, HPV-16 and MCV capsid
protein expression plasmids have been described previously
(Bergant and Banks, 2013), as was the HA-tagged ubiquitin
expression plasmid (Tomaic ́ et al., 2011).
Antibodies
The following primary antibodies were used in these studies:
mouse anti-TSG101 (C2; Santa Cruz Biotechnology), mouse anti-
HPV-16 L2 (2JGmab no. 5, Santa Cruz Biotechnology), rabbit anti-
HPV-16 L2 (kindly provided by Martin Müller), mouse anti-HA
(Roche), rabbit anti-alpha-actinin (H-300; Santa Cruz Biotechnology)
and appropriate secondary antibodies conjugated to horseradish
peroxidase (HRP; Dako) or rhodamine (Molecular Probes).
Cells and transfections
HEK293 (human embryonic kidney cells), U2OS (human osteo-
sarcoma cells), HaCaT (spontaneously immortalized human kera-
tinocyte cells) and 293TT cells were grown in Dulbecco's modiﬁed
Eagle's medium (DMEM) supplemented with 10% fetal bovine
serum (FBS), penicillin–streptomycin (100 U/mL) and glutamine
(300 mg/mL). For transient siRNA experiments, cells were trans-
fected using RNAiMAX (Invitrogen) with siRNA against TSG101
(ON-TARGETplus SMARTpool), and siRNA against HPV-18 E6/E7
(5_CAUUUACCAGCCCGACGAG, Dharmacon) as a control. For bind-
ing/coimmunoprecipitation assays cells were transfected with
DNA constructs using either calcium phosphate (Ca2PO4) precipi-
tation (Graham and van der Eb, 1973) for HEK293, 293TT and U2OS
or PEI for HaCaTs.
Fig. 6. TSG101 overexpression changes the ubiquitination pattern of HPV-16 L2. HEK293 cells were transfected with HPV-16 L2 GFP and HA-ubiquitin expression plasmids, in
the presence or absence of TSG101 GFP. After 24 h MG132 was added as indicated for a further 3 h to block the proteasome. The cells were then harvested and
immunoprecipitated using anti-HA conjugated agarose beads. The ubiquitinated L2 was then detected by Western blotting using anti HPV-16 L2 antibody (top panels). The
two lower panels show the inputs for HPV-16 L2 and TSG101.
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Fusion protein puriﬁcation and binding assays
GST-tagged fusion proteins were expressed and puriﬁed as
described previously (Thomas et al., 1996). TSG101 protein was
translated in vitro using a Promega TNT kit and radiolabelled with
[35S] methionine (Perkin Elmer). Equal amounts of in vitro trans-
lated proteins were added to GST fusion proteins bound to
glutathione agarose (Sigma) and incubated for 2 h at room
temperature. After extensive washing with E1A buffer (25 mM
HEPES, pH 7.0, 0.1% NP-40, 150 mM NaCl) bound proteins were
analyzed by SDS-PAGE and autoradiography.
Cellular protein extracts for use in GST pull-down assays were
generated using RIPA lysis buffer containing protease inhibitor
cocktail set I (Calbiochem). These were used in GST pull-down
assays as described above and, after extensive washing with E1A
buffer, the bound proteins were detected using SDS-PAGE and
Western blotting.
Coimmunoprecipitation
Cells were transfected with plasmids expressing GFP-tagged
TSG101 and FLAG-HA-tagged HPV-16 L2 expression plasmids.
After 24 h the cells were extracted with RIPA lysis buffer, and
extracts then incubated with anti-HA conjugated agarose beads
(Sigma) for 2 h on a rotating wheel at room temperature. The
beads were extensively washed with E1A buffer and the immu-
noprecipitates were analyzed for TSG101 by SDS-PAGE and Wes-
tern blotting using anti-TSG101 antibody.
Immunoﬂuorescence
HaCaT cells were transfected with FLAG-HA-tagged HPV-16 L2
expression plasmids and a GFP-tagged TSG101 expression plasmid.
After 24 h transfected cells were washed twice with phosphate-
buffered saline (PBS), ﬁxed with 4% paraformaldehyde in PBS for
15 min, washed again, and permeabilized in 0.1% Triton X-100 for
5 min. Cells were incubated with a mouse anti-HA antibody
(Roche) for 2 h at 37 1C, washed extensively with PBS, and
incubated for 20 min at 37 1C with rhodamine-conjugated goat
anti-mouse antibody (Molecular Probes). Slides were washed,
mounted in Vectashield mounting medium (VectorLaboratories)
and analyzed using a Zeiss LSM510 confocal microscope with two
lasers giving excitation lines at 480 nm and 510 nm. The data were
collected with a 60 objective oil immersion lens.
Pseudovirion (PsV) production
HPV-16, BPV-1 and MCV PsVs containing a luciferase reporter
plasmid were generated in 293TT cells as previously described
(Buck et al., 2005; Smith et al., 2005).
Infectivity assays
HaCaT cells were seeded in 12-well plates at a density
0.5105/well (DNA transfection) or 0.3105/well (siRNA trans-
fection). 24 h (DNA transfection) or 72 h (siRNA) after transfection,
PsVs were added at a concentration of 12 ng/mL. Infection was
monitored at 48 h by luminometric analysis of ﬁreﬂy luciferase
activity using the Luciferase Assay System kit (Promega). For each
type of PsV, infection was normalized to 100% as the value
obtained with cells transfected with control siRNA, and this was
used to calculate the percentage reduction following transfection
of the cells with TSG101 siRNA.
Ubiquitination assay
HEK293 cells were transfected with GFP-tagged HPV-16 L2,
GFP-tagged TSG101 and HA-tagged ubiquitin. After 24 h cells were
either treated with MG132 (Sigma) to rescue any proteins from
proteasome mediated degradation, or left untreated. Cells were
lysed and incubated with anti-HA conjugated agarose beads. After
extensive washing the bound proteins were detected using SDS-
PAGE and Western blotting.
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